|
1
|
Chooi YC, Ding C and Magkos F: The
epidemiology of obesity. Metabolism. 92:6–10. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hruby A and Hu FB: The epidemiology of
obesity: A big picture. Pharmacoeconomics. 33:673–689. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ji X, Chen J, Ye J, Xu S, Lin B and Hou K:
Epidemiological analysis of global and regional lung cancer
mortality: Based on 30-year data analysis of global burden disease
database. Healthcare (Basel). 11:29202023. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Chen Z, Fillmore CM, Hammerman PS, Kim CF
and Wong KK: Non-small-cell lung cancers: A heterogeneous set of
diseases. Nat Rev Cancer. 14:535–546. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lemjabbar-Alaoui H, Hassan OU, Yang YW and
Buchanan P: Lung cancer: Biology and treatment options. Biochim
Biophys Acta. 1856:189–210. 2015.PubMed/NCBI
|
|
6
|
Khaddour K, Gomez-Perez SL, Jain N, Patel
JD and Boumber Y: Obesity, sarcopenia, and outcomes in non-small
cell lung cancer patients treated with immune checkpoint inhibitors
and tyrosine kinase inhibitors. Front Oncol. 10:5763142020.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Petrelli F, Cortellini A, Indini A,
Tomasello G, Ghidini M, Nigro O, Salati M, Dottorini L, Iaculli A,
Varricchio A, et al: Association of obesity with survival outcomes
in patients with cancer: A systematic review and meta-analysis.
JAMA Netw Open. 4:e2135202021. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Zhang X, Liu Y, Shao H and Zheng X:
Obesity paradox in lung cancer prognosis: Evolving biological
insights and clinical implications. J Thorac Oncol. 12:1478–1488.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lennon H, Sperrin M, Badrick E and Renehan
AG: The obesity paradox in cancer: A review. Curr Oncol Rep.
18:562016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kawai T, Autieri MV and Scalia R: Adipose
tissue inflammation and metabolic dysfunction in obesity. Am J
Physiol Cell Physiol. 320:C375–C391. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Assumpção JAF, Pasquarelli-do-Nascimento
G, Duarte MSV, Bonamino MH and Magalhães KG: The ambiguous role of
obesity in oncology by promoting cancer but boosting antitumor
immunotherapy. J Biomed Sci. 29:122022. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Barbi J, Patnaik SK, Pabla S, Zollo R,
Smith RJ Jr, Sass SN, Srinivasan A, Petrucci C, Seager R, Conroy J,
et al: Visceral obesity promotes lung cancer progression-toward
resolution of the obesity paradox in lung cancer. J Thorac Oncol.
16:1333–1348. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nguyen HL, Geukens T, Maetens M, Aparicio
S, Bassez A, Borg A, Brock J, Broeks A, Caldas C, Cardoso F, et al:
Obesity-associated changes in molecular biology of primary breast
cancer. Nat Commun. 14:44182023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pati S, Irfan W, Jameel A, Ahmed S and
Shahid RK: Obesity and cancer: A current overview of epidemiology,
pathogenesis, outcomes, and management. Cancers (Basel).
15:4852023. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Yang Y, Dong J, Sun K, Zhao L, Zhao F,
Wang L and Jiao Y: Obesity and incidence of lung cancer: A
meta-analysis. Int J Cancer. 132:1162–1169. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choi EK, Park HB, Lee KH, Park JH,
Eisenhut M, van der Vliet HJ, Kim G and Shin JI: Body mass index
and 20 specific cancers: Re-analyses of dose-response meta-analyses
of observational studies. Ann Oncol. 29:749–757. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wu Z, Xie S, Wang F, Chen S, Su K, Li F,
Cui H, Cao W, Yu Y, Qin C, et al: BMI changes and the risk of lung
cancer in male never-smokers: A prospective cohort study. Cancer
Med. 11:1336–1346. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yu D, Zheng W, Johansson M, Lan Q, Park Y,
White E, Matthews CE, Sawada N, Gao YT, Robien K, et al: Overall
and central obesity and risk of lung cancer: A pooled analysis. J
Natl Cancer Inst. 110:831–842. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Zhu H and Zhang S: Body mass index and
lung cancer risk in never smokers: A meta-analysis. BMC Cancer.
18:6352018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang J, Xu H, Zhou S, Wang D, Zhu L, Hou
J, Tang J, Zhao J and Zhong S: Body mass index and mortality in
lung cancer patients: A systematic review and meta-analysis. Eur J
Clin Nutr. 72:4–17. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Neeland IJ, Poirier P and Després JP:
Cardiovascular and metabolic heterogeneity of obesity: Clinical
challenges and implications for management. Circulation.
137:1391–1406. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Caan BJ, Cespedes Feliciano EM and Kroenke
CH: The importance of body composition in explaining the overweight
paradox in cancer-counterpoint. Cancer Res. 78:1906–1912. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Khan M and Joseph F: Adipose tissue and
adipokines: The association with and application of adipokines in
obesity. Scientifica (Cairo). 2014:3285922014.PubMed/NCBI
|
|
24
|
Liu X, Yin L, Shen S and Hou Y:
Inflammation and cancer: Paradoxical roles in tumorigenesis and
implications in immunotherapies. Genes Dis. 10:151–164. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kahn BB and Flier JS: Obesity and insulin
resistance. J Clin Invest. 106:473–481. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Leroith D, Scheinman EJ and Bitton-Worms
K: The role of insulin and insulin-like growth factors in the
increased risk of cancer in diabetes. Rambam Maimonides Med J.
2:e00432011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhong W, Wang X, Wang Y, Sun G, Zhang J
and Li Z: Obesity and endocrine-related cancer: The important role
of IGF-1. Front Endocrinol (Lausanne). 14:10932572023. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rodriguez-Lara V and Avila-Costa MR: An
overview of lung cancer in women and the impact of estrogen in lung
carcinogenesis and lung cancer treatment. Front Med (Lausanne).
8:6001212021. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Savini I, Catani MV, Evangelista D,
Gasperi V and Avigliano L: Obesity-associated oxidative stress:
Strategies finalized to improve redox state. Int J Mol Sci.
14:10497–10538. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Usman M and Volpi EV: DNA damage in
obesity: Initiator, promoter and predictor of cancer. Mutat Res Rev
Mutat Res. 778:23–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kim JW, Kim JH and Lee YJ: The role of
adipokines in tumor progression and its association with obesity.
Biomedicines. 12:972024. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Sarfati D, Koczwara B and Jackson C: The
impact of comorbidity on cancer and its treatment. CA Cancer J
Clin. 66:337–350. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Søgaard M, Thomsen RW, Bossen KS, Sørensen
HT and Nørgaard M: The impact of comorbidity on cancer survival: A
review. Clin Epidemiol. 5 (Suppl 1):S3–S29. 2013. View Article : Google Scholar
|
|
34
|
Al-Jawaldeh A and Abbass MMS: Unhealthy
dietary habits and obesity: The major risk factors beyond
non-communicable diseases in the eastern mediterranean region.
Front Nutr. 9:8178082022. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Washington TB, Johnson VR, Kendrick K,
Ibrahim AA, Tu L, Sun K and Stanford FC: Disparities in access and
quality of obesity care. Gastroenterol Clin North Am. 52:429–441.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xiong A, Nie W, Cheng L, Zhong H, Chu T,
Zhong R, Lu J, Wang S, Xu J, Shen Y, et al: Association between
obesity and poor prognosis in patients receiving anlotinib for
advanced non-small cell lung cancer. Front Pharmacol.
13:8125552022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Nitsche L, Vedire Y, Kannisto E, Wang X,
Seager RJ, Pabla S, Patnaik SK and Yendamuri S: Visceral Obesity in
non-small cell lung cancer. Cancers (Basel). 14:34502022.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Lee CH, Lin C, Wang CY, Huang TC, Wu YY,
Chien WC and Chen JH: Premorbid BMI as a prognostic factor in
small-cell lung cancer-a single institute experience. Oncotarget.
9:24642–24652. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kwon YJ, Yoon YC, Kim HS, Cha MJ, Park S
and Lee JH: Prognostic significance of body mass index in
small-cell lung cancer: Exploring the relationship with skeletal
muscle status. J Cachexia Sarcopenia Muscle. 14:2939–2947. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Sutandyo N, Hanafi AR, Jayusman AM,
Kurniawati SA and Hanif MA: Overweight and Obesity are associated
with poorer survival among patients with advanced non-small cell
lung cancer receiving platinum-based chemotherapy. Int J Gen Med.
16:85–93. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Tu H, McQuade JL, Davies MA, Huang M, Xie
K, Ye Y, Chow WH, Rodriguez A and Wu X: Body mass index and
survival after cancer diagnosis: A pan-cancer cohort study of 114
430 patients with cancer. Innovation (Camb).
3:1003442022.PubMed/NCBI
|
|
42
|
Booth A, Magnuson A, Fouts J and Foster M:
Adipose tissue, obesity and adipokines: Role in cancer promotion.
Horm Mol Biol Clin Investig. 21:57–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Bocian-Jastrzębska A, Malczewska-Herman A
and Kos-Kudła B: Role of leptin and adiponectin in carcinogenesis.
Cancers (Basel). 15:42502023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Ramos-Nino ME: The role of chronic
inflammation in obesity-associated cancers. ISRN Oncol.
2013:6975212013.PubMed/NCBI
|
|
45
|
Wen X, Zhang B, Wu B, Xiao H, Li Z, Li R,
Xu X and Li T: Signaling pathways in obesity: Mechanisms and
therapeutic interventions. Signal Transduct Target Ther. 7:2982022.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lam VK, Bentzen SM, Mohindra P, Nichols
EM, Bhooshan N, Vyfhuis M, Scilla KA, Feigenberg SJ, Edelman MJ and
Feliciano JL: Obesity is associated with long-term improved
survival in definitively treated locally advanced non-small cell
lung cancer (NSCLC). Lung Cancer. 104:52–57. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Gallagher EJ and LeRoith D: Insulin,
insulin resistance, obesity, and cancer. Curr Diab Rep. 10:93–100.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Fukumoto K, Mori S, Shintani Y, Okami J,
Ito H, Ohtsuka T, Toyooka S, Mori T, Watanabe SI, Asamura H, et al:
Impact of the preoperative body mass index on the postoperative
outcomes in patients with completely resected non-small cell lung
cancer: A retrospective analysis of 16,503 cases in a Japanese lung
cancer registry study. Lung Cancer. 149:120–129. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
O'Rourke RW: Obesity and cancer: At the
crossroads of cellular metabolism and proliferation. Surg Obes
Relat Dis. 10:1208–1219. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Li M and Bu R: Biological support to
obesity paradox in renal cell carcinoma: A review. Urol Int.
104:837–848. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Björndahl M, Cao R, Nissen LJ, Clasper S,
Johnson LA, Xue Y, Zhou Z, Jackson D, Hansen AJ and Cao Y:
Insulin-like growth factors 1 and 2 induce lymphangiogenesis in
vivo. Proc Natl Acad Sci USA. 102:15593–15598. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wang Q, Tu H, Zhu M, Liang D, Ye Y, Chang
DW, Long Y and Wu X: Circulating obesity-driven biomarkers are
associated with risk of clear cell renal cell carcinoma: A
two-stage, case-control study. Carcinogenesis. 40:1191–1197. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kamat AM, Shock RP, Naya Y, Rosser CJ,
Slaton JW and Pisters LL: Prognostic value of body mass index in
patients undergoing nephrectomy for localized renal tumors.
Urology. 63:46–50. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Albiges L, Hakimi AA, Xie W, McKay RR,
Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, et
al: Body mass index and metastatic renal cell carcinoma: Clinical
and biological correlations. J Clin Oncol. 34:3655–3663. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Choi Y, Park B, Jeong BC, Seo SI, Jeon SS,
Choi HY, Adami HO, Lee JE and Lee HM: Body mass index and survival
in patients with renal cell carcinoma: A clinical-based cohort and
meta-analysis. Int J Cancer. 132:625–634. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Jeon HG, Jeong IG, Lee JH, Lee CJ, Kwak C,
Kim HH, Lee SE and Lee E: Prognostic value of body mass index in
Korean patients with renal cell carcinoma. J Urol. 183:448–454.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Choueiri TK, Xie W, Kollmannsberger CK,
Rini BI, McDermott DF, Knox JJ and Heng DY: The impact of body mass
index (BMI) and body surface area (BSA) on treatment outcome to
vascular endothelial growth factor (VEGF)-targeted therapy in
metastatic renal cell carcinoma: Results from a large international
collaboration. J Clin Oncol. 28 (15 Suppl):S45242010. View Article : Google Scholar
|
|
58
|
Naik GS, Waikar SS, Johnson AEW,
Buchbinder EI, Haq R, Hodi FS, Schoenfeld JD and Ott PA: Complex
inter-relationship of body mass index, gender and serum creatinine
on survival: Exploring the obesity paradox in melanoma patients
treated with checkpoint inhibition. J Immunother Cancer. 7:892019.
View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Donnelly D, Bajaj S, Yu J, Hsu M, Balar A,
Pavlick A, Weber J, Osman I and Zhong J: The complex relationship
between body mass index and response to immune checkpoint
inhibition in metastatic melanoma patients. J Immunother Cancer.
7:2222019. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Pencheva N, Buss C, Posada J, Merghoub T
and Tavazoie SF: Broad-spectrum therapeutic suppression of
metastatic melanoma through nuclear hormone receptor activation.
Cell. 156:986–1001. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
McQuade JL, Daniel CR, Hess KR, Mak C,
Wang DY, Rai RR, Park JJ, Haydu LE, Spencer C, Wongchenko M, et al:
Association of body-mass index and outcomes in patients with
metastatic melanoma treated with targeted therapy, immunotherapy,
or chemotherapy: A retrospective, multicohort analysis. Lancet
Oncol. 19:310–322. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Wang Z, Aguilar EG, Luna JI, Dunai C,
Khuat LT, Le C, Mirsoian A, Minnar CM, Stoffel KM, Sturgill IR, et
al: Paradoxical effects of obesity on T cell function during tumor
progression and PD-1 checkpoint blockade. Nat Med. 25:141–151.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Georgiadis MS, Steinberg SM, Hankins LA,
Ihde DC and Johnson BE: Obesity and therapy-related toxicity in
patients treated for small-cell lung cancer. J Natl Cancer Inst.
87:361–366. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Nattenmüller J, Wochner R, Muley T, Steins
M, Hummler S, Teucher B, Wiskemann J, Kauczor HU, Wielpütz MO and
Heussel CP: Prognostic impact of CT-quantified muscle and fat
distribution before and after first-line-chemotherapy in lung
cancer patients. PLoS One. 12:e01691362017. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Shepshelovich D, Xu W, Lu L, Fares A, Yang
P, Christiani D, Zhang J, Shiraishi K, Ryan BM, Chen C, et al: Body
mass index (BMI), BMI change, and overall survival in patients with
SCLC and NSCLC: A pooled analysis of the international lung cancer
consortium. J Thorac Oncol. 14:1594–1607. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Icard P, Schussler O, Loi M, Bobbio A,
Lupo AM, Wislez M, Iannelli A, Fournel L, Damotte D and Alifano M:
Pre-disease and pre-surgery BMI, weight loss and sarcopenia impact
survival of resected lung cancer independently of tumor stage.
Cancers (Basel). 12:2662020. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Jiang M, Fares AF, Shepshelovich D, Yang
P, Christiani D, Zhang J, Shiraishi K, Ryan BM, Chen C, Schwartz
AG, et al: The relationship between body-mass index and overall
survival in non-small cell lung cancer by sex, smoking status, and
race: A pooled analysis of 20,937 international lung cancer
consortium (ILCCO) patients. Lung Cancer. 152:58–65. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bethea TN, Rosenberg L, Charlot M,
O'Connor GT, Adams-Campbell LL and Palmer JR: Obesity in relation
to lung cancer incidence in African American women. Cancer Causes
Control. 24:1695–1703. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Kim HR, Kim SY, Kim CH, Yang SH, Lee JC,
Choi CM and Na II: Sex-specific incidence of EGFR mutation and its
association with age and obesity in lung adenocarcinomas: A
retrospective analysis. J Cancer Res Clin Oncol. 143:2283–2290.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Gremese E, Tolusso B, Gigante MR and
Ferraccioli G: Obesity as a risk and severity factor in rheumatic
diseases (autoimmune chronic inflammatory diseases). Front Immunol.
5:5762014. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Siopis G: Obesity: A comorbidity-acquired
immunodeficiency syndrome (CAIDS). Int Rev Immunol. 42:415–429.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Cao Y: Adipocyte and lipid metabolism in
cancer drug resistance. J Clin Invest. 129:3006–3017. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Havas KM, Milchevskaya V, Radic K, Alladin
A, Kafkia E, Garcia M, Stolte J, Klaus B, Rotmensz N, Gibson TJ, et
al: Metabolic shifts in residual breast cancer drive tumor
recurrence. J Clin Invest. 127:2091–2105. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Iwamoto H, Abe M, Yang Y, Cui D, Seki T,
Nakamura M, Hosaka K, Lim S, Wu J, He X, et al: Cancer lipid
metabolism confers antiangiogenic drug resistance. Cell Metab.
28:104–117.e5. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Hoy AJ, Nagarajan SR and Butler LM: Tumour
fatty acid metabolism in the context of therapy resistance and
obesity. Nat Rev Cancer. 21:753–766. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Camarda R, Zhou AY, Kohnz RA, Balakrishnan
S, Mahieu C, Anderton B, Eyob H, Kajimura S, Tward A, Krings G, et
al: Inhibition of fatty acid oxidation as a therapy for
MYC-overexpressing triple-negative breast cancer. Nat Med.
22:427–432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Huang Q, Wang Q, Li D, Wei X, Jia Y, Zhang
Z, Ai B, Cao X, Guo T and Liao Y: Co-administration of
20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI
resistance by decreasing SCD1 induced lipid accumulation in
non-small cell lung cancer. J Exp Clin Cancer Res. 38:1292019.
View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Watt MJ, Clark AK, Selth LA, Haynes VR,
Lister N, Rebello R, Porter LH, Niranjan B, Whitby ST, Lo J, et al:
Suppressing fatty acid uptake has therapeutic effects in
preclinical models of prostate cancer. Sci Transl Med.
11:eaau57582019. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Pascual G, Avgustinova A, Mejetta S,
Martin M, Castellanos A, Attolini CSO, Berenguer A, Prats N, Toll
A, Hueto JA, et al: Targeting metastasis-initiating cells through
the fatty acid receptor CD36. Nature. 541:41–45. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Buckley D, Duke G, Heuer TS, O'Farrell M,
Wagman AS, McCulloch W and Kemble G: Fatty acid synthase-Modern
tumor cell biology insights into a classical oncology target.
Pharmacol Ther. 177:23–31. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Zaytseva YY, Rychahou PG, Le AT, Scott TL,
Flight RM, Kim JT, Harris J, Liu J, Wang C, Morris AJ, et al:
Preclinical evaluation of novel fatty acid synthase inhibitors in
primary colorectal cancer cells and a patient-derived xenograft
model of colorectal cancer. Oncotarget. 9:24787–24800. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Sheng X, Parmentier JH, Tucci J, Pei H,
Cortez-Toledo O, Dieli-Conwright CM, Oberley MJ, Neely M, Orgel E,
Louie SG and Mittelman SD: Adipocytes sequester and metabolize the
chemotherapeutic daunorubicin. Mol Cancer Res. 15:1704–1713. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Bauerschlag DO, Maass N, Leonhardt P,
Verburg FA, Pecks U, Zeppernick F, Morgenroth A, Mottaghy FM, Tolba
R, Meinhold-Heerlein I and Bräutigam K: Fatty acid synthase
overexpression: Target for therapy and reversal of chemoresistance
in ovarian cancer. J Transl Med. 13:1462015. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Papaevangelou E, Almeida GS, Box C,
deSouza NM and Chung YL: The effect of FASN inhibition on the
growth and metabolism of a cisplatin-resistant ovarian carcinoma
model. Int J Cancer. 143:992–1002. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Altieri DC: Mitochondria on the move:
Emerging paradigms of organelle trafficking in tumour plasticity
and metastasis. Br J Cancer. 117:301–305. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wang H, Franco F, Tsui YC, Xie X, Trefny
MP, Zappasodi R, Mohmood SR, Fernández-García J, Tsai CH, Schulze
I, et al: CD36-mediated metabolic adaptation supports regulatory T
cell survival and function in tumors. Nat Immunol. 21:298–308.
2020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Ladanyi A, Mukherjee A, Kenny HA, Johnson
A, Mitra AK, Sundaresan S, Nieman KM, Pascual G, Benitah SA, Montag
A, et al: Adipocyte-induced CD36 expression drives ovarian cancer
progression and metastasis. Oncogene. 37:2285–2301. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Yuan H, Kopelovich L, Yin Y, Lu J and
Glazer RI: Drug-targeted inhibition of peroxisome
proliferator-activated receptor-gamma enhances the chemopreventive
effect of anti-estrogen therapy. Oncotarget. 3:345–356. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Cheng S, Qian K, Wang Y, Wang G, Liu X,
Xiao Y and Wang X: PPARγ inhibition regulates the cell cycle,
proliferation and motility of bladder cancer cells. J Cell Mol Med.
23:3724–3736. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Lou G, Song X, Yang F, Wu S, Wang J, Chen
Z and Lu Y: Exosomes derived from miR-122-modified adipose
tissue-derived MSCs increase chemosensitivity of hepatocellular
carcinoma. J Hematol Oncol. 8:1222015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Au Yeung CL, Co NN, Tsuruga T, Yeung TL,
Kwan SY, Leung CS, Li Y, Lu ES, Kwan K, Wong KK, et al: Exosomal
transfer of stroma-derived miR21 confers paclitaxel resistance in
ovarian cancer cells through targeting APAF1. Nat Commun.
7:111502016. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Polanski R, Hodgkinson CL, Fusi A, Nonaka
D, Priest L, Kelly P, Trapani F, Bishop PW, White A, Critchlow SE,
et al: Activity of the monocarboxylate transporter 1 inhibitor
AZD3965 in small cell lung cancer. Clin Cancer Res. 20:926–937.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Xie H, Hanai J, Ren JG, Kats L, Burgess K,
Bhargava P, Signoretti S, Billiard J, Duffy KJ, Grant A, et al:
Targeting lactate dehydrogenase-a inhibits tumorigenesis and tumor
progression in mouse models of lung cancer and impacts
tumor-initiating cells. Cell Metab. 19:795–809. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Karakas Y, Esin E, Lacin S, Ceyhan K,
Heper AO and Yalcin S: A case of acanthosis nigricans as a
paraneoplastic syndrome with squamous cell lung cancer. Onco
Targets Ther. 9:4815–4820. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Lawrenson R, Lao C, Brown L, Moosa L,
Chepulis L, Keenan R, Kidd J, Middleton K, Conaglen P, de Groot C,
et al: Management of patients with early stage lung cancer-why do
some patients not receive treatment with curative intent? BMC
Cancer. 20:1092020. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Plassmeier L, Hankir MK and Seyfried F:
Impact of excess body weight on postsurgical complications. Visc
Med. 37:287–297. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Tjeertes EKM, Hoeks SE, Beks SBJ,
Valentijn TM, Hoofwijk AGM and Stolker RJ: Obesity-a risk factor
for postoperative complications in general surgery? BMC
Anesthesiol. 15:1122015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Hodgson LE, Murphy PB and Hart N:
Respiratory management of the obese patient undergoing surgery. J
Thorac Dis. 7:943–952. 2015.PubMed/NCBI
|
|
99
|
Pierpont YN, Dinh TP, Salas RE, Johnson
EL, Wright TG, Robson MC and Payne WG: Obesity and surgical wound
healing: A current review. ISRN Obes. 2014:6389362014.PubMed/NCBI
|
|
100
|
De Camilli AR, Cadwell JB, Weiss H,
Tollinche LE, McFarlane D, Broach V, Leitao MM, Kitzler R and
Afonso AM: Perioperative considerations for cancer patients with
obesity: A narrative review. Trends Anaesth Crit Care. 46:33–41.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Lang LH, Parekh K, Tsui BYK and Maze M:
Perioperative management of the obese surgical patient. Br Med
Bull. 124:135–155. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Vedire Y, Kalvapudi S and Yendamuri S:
Obesity and lung cancer-a narrative review. J Thorac Dis.
15:2806–2823. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Alifano M, Daffré E, Iannelli A, Brouchet
L, Falcoz PE, Le Pimpec Barthes F, Bernard A, Pages PB, Thomas PA,
Dahan M and Porcher R: The reality of lung cancer paradox: The
impact of body mass index on long-term survival of resected lung
cancer. A French nationwide analysis from the epithor database.
Cancers (Basel). 13:45742021. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Tong C, Li T, Shen Y, Zhu H, Zheng J and
Wu J: Obesity does not increase perioperative outcomes in older
patients undergoing thoracoscopic anatomic lung cancer surgery.
Front Oncol. 12:8814672022. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Guerrera F, Lyberis P, Lausi PO,
Cristofori RC, Giobbe R, Molinatti M, Filosso PL, Curcio C, Crisci
R and Ruffini E; on the behalf of the Italian VATS Group, : Does
morbid obesity influence perioperative outcomes after
video-assisted thoracic surgery (VATS) lobectomy for non-small cell
lung cancer? Analysis of the Italian VATS group registry. Surg
Endosc. 36:3567–3573. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Lee JH, Yoon YC and Kim HS, Cha MJ, Kim
JH, Kim K and Kim HS: Obesity is associated with improved
postoperative overall survival, independent of skeletal muscle mass
in lung adenocarcinoma. J Cachexia Sarcopenia Muscle. 13:1076–1086.
2022. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Tulinský L, Sengul I, Ihnát P, Ostruszka
P, Toman D, Guňková P, Pelikán A and Sengul D: Obesity in cases
undergoing the surgical procedure of lung lobectomy: Risk or
benefit? Rev Assoc Med Bras (1992). 68:1090–1095. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Seder CW, Farrokhyar F, Nayak R, Baste JM,
Patel Y, Agzarian J, Finley CJ, Shargall Y, Thomas PA, Dahan M, et
al: Robotic vs thoracoscopic anatomic lung resection in obese
patients: A propensity-adjusted analysis. Ann Thorac Surg.
114:1879–1885. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Leonardi B, Forte S, Natale G, Messina G,
Rainone A, Opromolla G, Puca MA, Grande M, Martone M, Leone F, et
al: One-lung ventilation in obese patients undergoing thoracoscopic
lobectomy for lung cancer. Thorac Cancer. 14:281–288. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Silvestris N, Argentiero A, Natalicchio A,
D'Oronzo S, Beretta GD, Acquati S, Adinolfi V, Di Bartolo P, Danesi
R, Faggiano A, et al: Antineoplastic dosing in overweight and obese
cancer patients: an associazione italiana oncologia medica
(AIOM)/associazione medici diabetologi (AMD)/Società Italiana
Endocrinologia (SIE)/Società Italiana Farmacologia (SIF)
multidisciplinary consensus position paper. ESMO Open.
6:1001532021. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Barras M and Legg A: Drug dosing in obese
adults. Aust Prescr. 40:189–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Griggs JJ, Bohlke K, Balaban EP, Dignam
JJ, Hall ET, Harvey RD, Hecht DP, Klute KA, Morrison VA, Pini TM,
et al: Appropriate systemic therapy dosing for obese adult patients
with cancer: ASCO guideline update. J Clin Oncol. 39:2037–2048.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Dent SF, Kikuchi R, Kondapalli L,
Ismail-Khan R, Brezden-Masley C, Barac A and Fradley M: Optimizing
cardiovascular health in patients with cancer: A practical review
of risk assessment, monitoring, and prevention of cancer
treatment-related cardiovascular toxicity. Am Soc Clin Oncol Educ
Book. 40:1–15. 2020.PubMed/NCBI
|
|
114
|
Kicken MP, Kilinc HD, Cramer-van der Welle
CM, Houterman S, van den Borne BEEM, Smit AAJ, van de Garde EMW and
Deenen MJ; Santeon NSCLC study group, : The association of body
mass index with safety and effectiveness of first-line
carboplatin-based chemotherapy in patients with metastatic
non-small cell lung cancer. Cancer Treat Res Commun. 34:1006762023.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Kashiwabara K, Yamane H and Tanaka H:
Toxicity and prognosis in overweight and obese women with lung
cancer receiving carboplatin-paclitaxel doublet chemotherapy.
Cancer Invest. 31:251–257. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Georgakopoulou VE, Garmpis N, Mermigkis D,
Damaskos C, Chlapoutakis S, Mantzouranis K, Gkoufa A, Papageorgiou
C, Garmpi A, Makrodimitri S, et al: Pulmonary adverse events due to
immune checkpoint inhibitors: A literature review. Monaldi Arch
Chest Dis. 92:2021.PubMed/NCBI
|
|
117
|
Vick LV, Canter RJ, Monjazeb AM and Murphy
WJ: Multifaceted effects of obesity on cancer immunotherapies:
Bridging preclinical models and clinical data. Semin Cancer Biol.
95:88–102. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Woodall MJ, Neumann S, Campbell K,
Pattison ST and Young SL: The effects of obesity on anti-cancer
immunity and cancer immunotherapy. Cancers (Basel). 12:12302020.
View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Sanhueza S, Simón L, Cifuentes M and Quest
AFG: The adipocyte-macrophage relationship in cancer: A potential
target for antioxidant therapy. Antioxidants (Basel). 12:1262023.
View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Hahn AW, Venkatesh N, Msaouel P and
McQuade JL: The influence of obesity on outcomes with immune
checkpoint blockade: Clinical evidence and potential biological
mechanisms. Cells. 12:25512023. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Guo H, Lin XY, Feng S, Wang C, Yuan LQ,
Sheng XG and Li DP: Prognostic value of obesity in patients with
cancer treated with immune checkpoint inhibitors: An updated
meta-analysis and systematic review. Mol Clin Oncol. 20:52023.
View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Leiter A, Carroll E, De Alwis S, Brooks D,
Shimol JB, Eisenberg E, Wisnivesky JP, Galsky MD and Gallagher EJ:
Metabolic disease and adverse events from immune checkpoint
inhibitors. Eur J Endocrinol. 184:857–865. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Zhang T, Li S, Chang J, Qin Y and Li C:
Impact of BMI on the survival outcomes of non-small cell lung
cancer patients treated with immune checkpoint inhibitors: A
meta-analysis. BMC Cancer. 23:10232023. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Baskar R, Lee KA, Yeo R and Yeoh KW:
Cancer and radiation therapy: Current advances and future
directions. Int J Med Sci. 9:193–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Winters E and Poole C: Challenges and
impact of patient obesity in radiation therapy practice.
Radiography (Lond). 26:e158–e163. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Mercieca S, Belderbos JSA and van Herk M:
Challenges in the target volume definition of lung cancer
radiotherapy. Transl Lung Cancer Res. 10:1983–1998. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Ross KH, Gogineni K, Subhedar PD, Lin JY
and McCullough LE: Obesity and cancer treatment efficacy: Existing
challenges and opportunities. Cance. 125:1588–1592. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Wang K and Tepper JE: Radiation
therapy-associated toxicity: Etiology, management, and prevention.
CA Cancer J Clin. 71:437–454. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Welsh J, Thomas J, Shah D, Allen PK, Wei
X, Mitchell K, Gao S, Balter P, Komaki R and Chang JY: Obesity
increases the risk of chest wall pain from thoracic stereotactic
body radiation therapy. Int J Radiat Oncol Biol Phys. 81:91–96.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Lempesis IG, Karlafti E, Papalexis P,
Fotakopoulos G, Tarantinos K, Lekakis V, Papadakos SP, Cholongitas
E and Georgakopoulou VE: COVID-19 and liver injury in individuals
with obesity. World J Gastroenterol. 29:908–916. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Lempesis IG and Georgakopoulou VE:
Implications of obesity and adiposopathy on respiratory infections;
focus on emerging challenges. World J Clin Cases. 11:2925–2933.
2023. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Lempesis IG, Varrias D, Sagris M, Attaran
RR, Altin ES, Bakoyiannis C, Palaiodimos L, Dalamaga M and
Kokkinidis DG: Obesity and peripheral artery disease: Current
evidence and controversies. Curr Obes Rep. 12:264–279. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Lempesis IG, Georgakopoulou VE, Papalexis
P, Chrousos GP and Spandidos DA: Role of stress in the pathogenesis
of cancer (Review). Int J Oncol. 63:1242023. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Lempesis IG, Hoebers N, Essers Y, Jocken
JWE, Dineen R, Blaak EE, Manolopoulos KN and Goossens GH: Distinct
inflammatory signatures of upper and lower body adipose tissue and
adipocytes in women with normal weight or obesity. Front Endocrinol
(Lausanne). 14:12057992023. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Lempesis IG, van Meijel RLJ, Manolopoulos
KN and Goossens GH: Oxygenation of adipose tissue: A human
perspective. Acta Physiol (Oxf). 228:e132982020. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Lempesis IG and Georgakopoulou VE:
Physiopathological mechanisms related to inflammation in obesity
and type 2 diabetes mellitus. World J Exp Med. 13:7–16. 2023.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Lempesis IG, Liu J and Dalamaga M: The
catcher in the gut: Tirzepatide, a dual incretin analog for the
treatment of type 2 diabetes mellitus and obesity. Metabol Open.
16:1002202022. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Lempesis IG, Tsilingiris D, Liu J and
Dalamaga M: Of mice and men: Considerations on adipose tissue
physiology in animal models of obesity and human studies. Metabol
Open. 15:1002082022. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Georgakopoulou VE, Lempesis IG and
Spandidos DA: The parallel lives of pandemics: COVID-19 and
obesity. Exp Ther Med. 27:1842024. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Longo M, Zatterale F, Naderi J, Parrillo
L, Formisano P, Raciti GA, Beguinot F and Miele C: Adipose tissue
dysfunction as determinant of obesity-associated metabolic
complications. Int J Mol Sci. 20:23582019. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Daquinag AC, Tseng C, Zhang Y,
Amaya-Manzanares F, Florez F, Dadbin A, Zhang T and Kolonin MG:
Targeted proapoptotic peptides depleting adipose stromal cells
inhibit tumor growth. Mol Ther. 24:34–40. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Jin X, Qiu T, Li L, Yu R, Chen X, Li C,
Proud CG and Jiang T: Pathophysiology of obesity and its associated
diseases. Acta Pharm Sin B. 13:2403–2424. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Capurso C and Capurso A: From excess
adiposity to insulin resistance: The role of free fatty acids.
Vascul Pharmacol. 57:91–97. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Jung UJ and Choi MS: Obesity and its
metabolic complications: The role of adipokines and the
relationship between obesity, inflammation, insulin resistance,
dyslipidemia and nonalcoholic fatty liver disease. Int J Mol Sci.
15:6184–6223. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Cavaliere G, Cimmino F, Trinchese G,
Catapano A, Petrella L, D'Angelo M, Lucchin L and Mollica MP: From
obesity-induced low-grade inflammation to lipotoxicity and
mitochondrial dysfunction: Altered multi-crosstalk between adipose
tissue and metabolically active organs. Antioxidants (Basel).
12:11722023. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Divella R, De Luca R, Abbate I, Naglieri E
and Daniele A: Obesity and cancer: The role of adipose tissue and
adipo-cytokines-induced chronic inflammation. J Cancer.
7:2346–2359. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Himbert C, Delphan M, Scherer D, Bowers
LW, Hursting S and Ulrich CM: Signals from the adipose
microenvironment and the obesity-cancer link-a systematic review.
Cancer Prev Res (Phila). 10:494–506. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Fantuzzi G: Adipose tissue, adipokines,
and inflammation. J Allergy Clin Immunol. 115:911–920. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Louie SM, Roberts LS and Nomura DK:
Mechanisms linking obesity and cancer. Biochim Biophys Acta.
1831:1499–1508. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Dalamaga M, Diakopoulos KN and Mantzoros
CS: The role of adiponectin in cancer: A review of current
evidence. Endocr Rev. 33:547–594. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Nigro E, Scudiero O, Monaco ML, Palmieri
A, Mazzarella G, Costagliola C, Bianco A and Daniele A: New insight
into adiponectin role in obesity and obesity-related diseases.
Biomed Res Int. 2014:6589132014. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Parida S, Siddharth S and Sharma D:
Adiponectin, obesity, and cancer: Clash of the bigwigs in health
and disease. Int J Mol Sci. 20:25192019. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Dutta D, Ghosh S, Pandit K, Mukhopadhyay P
and Chowdhury S: Leptin and cancer: Pathogenesis and modulation.
Indian J Endocrinol Metab. 16 (Suppl 3):S596–S600. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Lang K and Ratke J: Leptin and
Adiponectin: New players in the field of tumor cell and leukocyte
migration. Cell Commun Signal. 7:272009. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Iikuni N, Lam QLK, Lu L, Matarese G and La
Cava A: Leptin and inflammation. Curr Immunol Rev. 4:70–79. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Mullen M and Gonzalez-Perez RR:
Leptin-induced JAK/STAT signaling and cancer growth. Vaccines
(Basel). 4:262016. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Cho YK, Lee Y and Jung CH: Pathogenesis,
murine models, and clinical implications of metabolically healthy
obesity. Int J Mol Sci. 23:96142022. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Blüher M: Metabolically healthy obesity.
Endocr Rev. 41:bnaa0042020. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Lin TY, Chen YF, Wu WT, Han DS, Tsai IC,
Chang KV and Özçakar L: Impact of sarcopenia on the prognosis and
treatment of lung cancer: An umbrella review. Discov Oncol.
13:1152022. View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Shao F, Chen Y, Xu H, Chen X, Zhou J, Wu
Y, Tang Y, Wang Z, Zhang R, Lange T, et al: Metabolic obesity
phenotypes and risk of lung cancer: A prospective cohort study of
450,482 UK Biobank participants. Nutrients. 14:33702022. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Malki A, Shaik RA and Sami W: Association
between metabolically healthy obesity and metastasis in lung cancer
patients-a systematic review and meta-analysis. Front Endocrinol
(Lausanne). 14:12384592023. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Sørensen J: Lung cancer cachexia: Can
molecular understanding guide clinical management? Integr Cancer
Ther. 17:1000–1008. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Anjanappa M, Corden M, Green A, Roberts D,
Hoskin P, McWilliam A and Choudhury A: Sarcopenia in cancer:
Risking more than muscle loss. Tech Innov Patient Support Radiat
Oncol. 16:50–57. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Peixoto da Silva S, Santos JMO, Costa E
Silva MP, Gil da Costa RM and Medeiros R: Cancer cachexia and its
pathophysiology: Links with sarcopenia, anorexia and asthenia. J
Cachexia Sarcopenia Muscle. 11:619–635. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Kim EY, Lee HY, Kim KW, Lee JI, Kim YS,
Choi WJ and Kim JH: Preoperative computed tomography-determined
sarcopenia and postoperative outcome after surgery for non-small
cell lung cancer. Scand J Surg. 107:244–251. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Bozzetti F: Forcing the vicious circle:
Sarcopenia increases toxicity, decreases response to chemotherapy
and worsens with chemotherapy. Ann Oncol. 28:2107–2118. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Law ML: Cancer cachexia: Pathophysiology
and association with cancer-related pain. Front Pain Res
(Lausanne). 3:9712952022. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Vaughan VC, Martin P and Lewandowski PA:
Cancer cachexia: Impact, mechanisms and emerging treatments. J
Cachexia Sarcopenia Muscle. 4:95–109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Kidd AC, Skrzypski M, Jamal-Hanjani M and
Blyth KG: Cancer cachexia in thoracic malignancy: A narrative
review. Curr Opin Support Palliat Care. 13:316–322. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Ding C, Chan Z and Magkos F: Lean, but not
healthy: The ‘metabolically obese, normal-weight’ phenotype. Curr
Opin Clin Nutr Metab Care. 19:408–417. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Donohoe CL, Doyle SL and Reynolds JV:
Visceral adiposity, insulin resistance and cancer risk. Diabetol
Metab Syndr. 3:122011. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Crudele L, Piccinin E and Moschetta A:
Visceral adiposity and cancer: Role in pathogenesis and prognosis.
Nutrients. 13:21012021. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Park JE, Jo J, Youk J, Kim M, Yoon SH,
Keam B, Kim TM and Kim DW: Prognostic utility of body composition
parameters based on computed tomography analysis of advanced
non-small cell lung cancer treated with immune checkpoint
inhibitors. Insights Imaging. 14:1822023. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Popinat G, Cousse S, Goldfarb L, Becker S,
Gardin I, Salaün M, Thureau S, Vera P, Guisier F and Decazes P:
Sub-cutaneous Fat Mass measured on multislice computed tomography
of pretreatment PET/CT is a prognostic factor of stage IV non-small
cell lung cancer treated by nivolumab. Oncoimmunology.
8:e15801282019. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Magri V, Gottfried T, Di Segni M, Urban D,
Peled M, Daher S, Stoff R, Bar J and Onn A: Correlation of body
composition by computerized tomography and metabolic parameters
with survival of nivolumab-treated lung cancer patients. Cancer
Manag Res. 11:8201–8207. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Khan A, Welman CJ, Abed A, O'Hanlon S,
Redfern A, Azim S, Lopez P, Singh F and Khattak A: Association of
computed tomography measures of muscle and adipose tissue and
progressive changes throughout treatment with clinical endpoints in
patients with advanced lung cancer treated with immune checkpoint
inhibitors. Cancers (Basel). 15:13822023. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Park G, Song K, Choi Y, Oh JS, Choi HS,
Suh J, Kwon A, Kim HS and Chae HW: Sex Hormone-binding globulin is
associated with obesity and dyslipidemia in prepubertal children.
Children (Basel). 7:2722020.PubMed/NCBI
|
|
178
|
Musial C, Zaucha R, Kuban-Jankowska A,
Konieczna L, Belka M, Marino Gammazza A, Baczek T, Cappello F,
Wozniak M and Gorska-Ponikowska M: Plausible role of estrogens in
pathogenesis, progression and therapy of lung cancer. Int J Environ
Res Public Health. 18:6482021. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Stabile LP, Davis AL, Gubish CT, Hopkins
TM, Luketich JD, Christie N, Finkelstein S and Siegfried JM: Human
non-small cell lung tumors and cells derived from normal lung
express both estrogen receptor alpha and beta and show biological
responses to estrogen. Cancer Res. 62:2141–2150. 2002.PubMed/NCBI
|
|
180
|
McKenzie F, Biessy C, Ferrari P, Freisling
H, Rinaldi S, Chajès V, Dahm CC, Overvad K, Dossus L, Lagiou P, et
al: Healthy lifestyle and risk of cancer in the European
prospective investigation into cancer and nutrition cohort study.
Medicine (Baltimore). 95:e28502016. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Rock CL, Thomson C, Gansler T, Gapstur SM,
McCullough ML, Patel AV, Andrews KS, Bandera EV, Spees CK, Robien
K, et al: American Cancer Society guideline for diet and physical
activity for cancer prevention. CA Cancer J Clin. 70:245–271. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Khalil WJ, Akeblersane M, Khan AS, Moin
ASM and Butler AE: Environmental pollution and the risk of
developing metabolic disorders: obesity and diabetes. Int J Mol
Sci. 24:88702023. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Shi X, Zheng Y, Cui H, Zhang Y and Jiang
M: Exposure to outdoor and indoor air pollution and risk of
overweight and obesity across different life periods: A review.
Ecotoxicol Environ Saf. 242:1138932022. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Holme JA, Vondráček J, Machala M,
Lagadic-Gossmann D, Vogel CFA, Le Ferrec E, Sparfel L and Øvrevik
J: Lung cancer associated with combustion particles and fine
particulate matter (PM2.5)-The roles of polycyclic
aromatic hydrocarbons (PAHs) and the aryl hydrocarbon receptor
(AhR). Biochem Pharmacol. 216:1158012023. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Bhattacharjee P, Paul S and Bhattacharjee
P: Risk of occupational exposure to asbestos, silicon and arsenic
on pulmonary disorders: Understanding the genetic-epigenetic
interplay and future prospects. Environ Res. 147:425–434. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Malone ER, Oliva M, Sabatini PJB, Stockley
TL and Siu LL: Molecular profiling for precision cancer therapies.
Genome Med. 12:82020. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Li MSC, Mok KKS and Mok TSK: Developments
in targeted therapy & immunotherapy-how non-small cell lung
cancer management will change in the next decade: A narrative
review. Ann Transl Med. 11:3582023. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Rippe JM: Lifestyle medicine: The health
promoting power of daily habits and practices. Am J Lifestyle Med.
12:499–512. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Ko C and Chaudhry S: The need for a
multidisciplinary approach to cancer care. J Surg Res. 105:53–57.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Berardi R, Morgese F, Rinaldi S, Torniai
M, Mentrasti G, Scortichini L and Giampieri R: Benefits and
limitations of a multidisciplinary approach in cancer patient
management. Cancer Manag Res. 12:9363–9374. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Manisalidis I, Stavropoulou E,
Stavropoulos A and Bezirtzoglou E: Environmental and health impacts
of air pollution: A review. Front Public Health. 8:142020.
View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Sánchez-Romero LM, Penko J, Coxson PG,
Fernández A, Mason A, Moran AE, Ávila-Burgos L, Odden M, Barquera S
and Bibbins-Domingo K: Projected impact of mexico's sugar-sweetened
beverage tax policy on diabetes and cardiovascular disease: A
modeling study. PLoS Med. 13:e10021582016. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Cecchini M and Warin L: Impact of food
labelling systems on food choices and eating behaviours: A
systematic review and meta-analysis of randomized studies. Obes
Rev. 17:201–210. 2016. View Article : Google Scholar : PubMed/NCBI
|
